Valuation dashboard for Integer Holdings Corporation (ITGR) with P/E 42.48, P/B 2.50, EV/EBITDA 19.7 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures.
What would it be worth at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 42.5× · Multiples range: $91.46 · $101.65.
At the decade median (34.1×) $102 (-20 %); at its sector median (30.7×) $91 (-28 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Integer Holdings Corporation reported revenue of $1.85B in the most recent fiscal year, growing at a 5-year CAGR of 11.5%. Net income reached $102.8M, with a 5.9% 5-year CAGR.
Trailing-twelve-month margins: gross margin 23.6%, operating margin 8.2%, net margin 5.7%.
At $126.59 (closing price, October 30, 2026), ITGR trades at a P/E of 42.48 and an ROE of 6.02%. Market capitalisation stands at $4.3B.
Balance sheet quality for ITGR: debt-to-equity ratio of 0.78, current ratio of 3.98 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 42.48 |
| Price / Book | 2.50 |
| EV / EBITDA | 19.7 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ITGR | Integer Holdings Corporation | $4.3B | 42.48 | 2.50 | 6.0% |
| LIVN | LivaNova PLC | $4.3B | 23.29 | 3.28 | 15.4% |
| ADUS | Addus HomeCare Corporation | $2.3B | 22.02 | 2.02 | 9.6% |
| UFPT | UFP Technologies, Inc. | $2.2B | 30.69 | 4.76 | 16.7% |
| RXRX | Recursion Pharmaceuticals, Inc. | $2.4B | 2.35 | -50.4% | |
| CON | Concentra Group Holdings Parent, Inc. | $5.1B | 26.22 | 10.72 | 47.3% |
| HAE | Haemonetics Corporation | $5.4B | 58.65 | 6.48 | 11.3% |
Price
| Price | $126.59 (closing price, October 30, 2026) |
| Market Cap | $4.3B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 6.02% |
| Return on Invested Capital | 4.47% |
| Return on Assets | 3.06% |
| Gross Margin | 23.58% |
| Operating Margin | 8.17% |
| Net Margin | 5.68% |
Related companies: LIVN · ADUS · UFPT · RXRX · CON · HAE
Explore sector: Healthcare · Medical - Devices
More sections of ITGR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks